The development of new cancer therapies has been proceeding at
an astounding rate. These advancements have led to publishing
a second edition of Treating Cancer with Immunotherapy and
Targeted Therapy two years after the first edition.
A more comprehensive understanding of the process of
metastasis has unfolded, leading to the prospect of developing
drugs targeting metastasis. The role of cancer stem cells in the
process is also discussed.

Many new therapies are discussed. An overall theme appears
to be that they are most effective in combination with other
therapies. Combination therapies have led to a reexamination
and renaissance in the use of cancer vaccines. Advances in
messenger RNA technology have resulted in the development of
highly effective mRNA vaccines.

The uses of oncolytic viruses and bispecific antibodies represent
new approaches to immunotherapy. Applying CRISPR
technology to cancer therapy appears promising but is only in
the very early stages of development. The microbiome has vast
influences on human health, the immune system, and cancer
development, and the microbiome’s composition has shown to
affect the outcome of cancer therapies.

The field of cancer therapy is constantly evolving, and this book
is a concise summary of a vast field.

Updates: Subsequent issues of this newsletter will provide new developments in the fields of cancer immunotherapy and targeted therapy since the publication of the second edition.